埃弗雷斯特医药公司报告了针对个性化mRNA癌症疫苗EVM16的早期试验结果. Everest Medicines reports positive early trial results for personalized mRNA cancer vaccine EVM16.

埃弗雷斯特医药公司报告了其个性化mRNA癌症疫苗EVM16的第一阶段试验中早期积极结果. Everest Medicines reported positive early results from a phase 1 trial of its personalized mRNA cancer vaccine, EVM16. 在对9名患有晚期固体瘤且已用完标准治疗的患者进行的一项研究中,该疫苗显示出良好的安全性并引发强烈的免疫反应. In a study of nine patients with advanced solid tumors who had exhausted standard treatments, the vaccine showed a favorable safety profile and triggered strong immune responses. 预先数据显示,一些患者已确认部分反应和稳定疾病,突出表明该药物有治疗目前不对当前疗法产生反应的潜在作用. Preliminary data indicated a confirmed partial response and stable disease in some patients, highlighting its potential for treating patients unresponsive to current therapies.